Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease

Retina

Volumn 28, Issue 8, 2008, Pages 1151-1158

  Wong, Lisa J ^a,b   Desai, Rajen U ^a   Jain, Atul ^a   Feliciano, David ^a   Moshfeghi, Darius M ^a   Sanislo, Steven R ^a,c   Blumenkranz, Mark S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Adverse events; Avastin; Bevacizumab; Choroidal neovascularization; Diabetic macular edema; Macular degeneration; Neovascular glaucoma; Retinal pigment epithelial detachment; Retinal pigment epithelial tear; Retinal vascular occlusion

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRANCH RETINAL ARTERY OCCLUSION; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CHOROID DISEASE; CORNEA EDEMA; CORNEAL EPITHELIAL TOXICITY; DIABETIC MACULAR EDEMA; DRUG TOLERANCE; ERYTHEMA; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE TOXICITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NAUSEA AND VOMITING; NEOVASCULAR GLAUCOMA; OCULAR PRURITUS; PERIORBITAL ERYTHEMA; PERIORBITAL PRURITIS; RETINA DETACHMENT; RETINA DISEASE; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA TEAR; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VITREOUS HEMORRHAGE; VON HIPPEL LINDAU DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EYE DISEASE; INJECTION; PIGMENT EPITHELIUM; RETINA BLOOD VESSEL; RETINA MACULA DEGENERATION; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROID DISEASES; CHOROIDAL NEOVASCULARIZATION; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; HYPERTENSION; INJECTIONS; MACULAR DEGENERATION; MALE; RETINAL DETACHMENT; RETINAL DISEASES; RETINAL PERFORATIONS; RETINAL PIGMENT EPITHELIUM; RETINAL VESSELS; RETROSPECTIVE STUDIES; VITREOUS BODY;

EID: 58149240172     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31817e100f     Document Type: Article

References (22)

1. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
4. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
6. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
7. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160.
8. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-625.
9. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, Sanchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol 2007;22:109-125.
10. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81- 87.
11. Mitka M. Study aims to clarify efficacy, safety of eye drug treatments. JAMA 2007;297:1538-1539.
12. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol 2006;47:4569-4578.
13. Fung AE, Rosenfeld PJ, Reichel EZ. The intravitreal bevaci-zumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
14. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.
15. Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology 1999;106:1780 -1785.
16. Schultz-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities "hand motion" and "counting fingers" can be quantified with the Freiburg Visual Acuity Test. Invest Ophthalmol Vis Sci 2006;106:1236-1240.
17. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056.
18. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
19. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
20. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27:541-551.
21. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007;27:523-534.
22. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2007;27:535-540.